Leverage Your Impact - podcast episode cover

Leverage Your Impact

Aug 12, 202453 minSeason 1Ep. 294
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

Welcome to the latest episode of Try Not 2 Blink. In today's discussion, hosts Roya and Sheila will share recently published research in retinal ophthalmology. They will review the good, bad, and ugly and how it relates to clinical care. Among the topics covered will be the potential benefits of melatonin in reducing the risk of developing and progressing age-related macular degeneration (AMD), as well as why aspirin is not recommended for patients with AMD.

Then they welcome Dr. George Magrath to the show, a distinguished ocular oncology ophthalmologist and CEO of Ocuphire. Dr. Magrath will review the steps to increase his leverage on healthcare by obtaining "game-changing" higher education; he will give his pearls on looking for retinal changes and what the future holds for treating diabetic retinopathy.


Tune in next week for another engaging and lighthearted episode with Roya and Sheila on Try Not 2 Blink.

We value your input! If you have suggestions for topics or potential guests you would like to see featured on Try Not 2 Blink, please email us at [email protected] or click here to share your ideas.

SOURCES

Dr. George Magrath: LinkedIn

Dr. George Magrath: MUSC

Dr. Magrath appointed CEO/Director of Ocuphire

Interview with Dr. Magrath

Zeta 1 + APX3330

Good, Bad, Ugly

Ozempic and eye health

Melanoma Tips

Aura Pharma

Try Not to Blink Podcast  is powered by Valley Contax



For the best experience, listen in Metacast app for iOS or Android
Open in Metacast
Leverage Your Impact | Try Not To Blink podcast - Listen or read transcript on Metacast